Researchers have developed a new treatment option for men suffering from benign prostatic hyperplasia (BPH), a condition that causes urinary difficulties. Rivermark Medical’s FloStent™ System is a non-surgical device designed to alleviate lower urinary tract symptoms associated with BPH. This innovative approach allows for outpatient treatment during a routine procedure and can be easily adjusted or removed if necessary, preserving future treatment options for patients.

This new therapy could significantly benefit men experiencing BPH symptoms, which can include frequent urination, urgency, and weak urine flow. The FloStent aims to provide a simple and effective first-line treatment that may lead to quicker recovery times and lasting results. With millions of men facing BPH, this device could offer a much-needed solution for those who are currently unsure about their treatment options.

The FloStent is currently undergoing a pivotal clinical trial known as RAPID III, following positive results from an earlier study, RAPID II. While the results so far are promising, it’s important to note that the FloStent is still in the investigational phase and has not yet received regulatory approval for widespread use. This means that while the potential is there, more research is needed to confirm its effectiveness and safety in a larger population.

For men dealing with BPH, keeping an eye on developments like the FloStent may be wise. If you experience symptoms, discussing treatment options with a healthcare provider is essential. They can help navigate the available therapies and determine the best approach for your individual needs.

Source: globenewswire.com